Quest PharmaTech announces sale of non-core assets
Quest disengages completely from China
11-Aug-2006
Continuing the Company's effort to sell its non-core assets, Quest also announced the sale of its AntiCort rights back to Samaritan Pharmaceuticals, Inc. for gross proceeds of $50,000 U.S. and 50,000 common shares of Samaritan. The sale is part of an arrangement whereby Quest has agreed to discontinue its statement of claim that was brought against Samaritan in March, 2006.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.